Short version first:
- Camzyos is mavacamten, an FDA-approved drug for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It’s marketed by Bristol Myers Squibb (MyoKardia was the original developer and was bought by BMS). It works by inhibiting cardiac myosin to reduce the heart’s contractility and the LVOT obstruction.
- Aficamten is a separate, investigational drug (a cardiac myosin inhibitor) developed by Cytokinetics. It’s not approved yet. If your doctor mentioned aficamten, they’re talking about a potential alternative in development, not something you can get today outside of a trial.
If you want, I can tailor this to your situation, but here’s a bit more detail so you can talk with your doctor.
What Camzyos (mavacamten) is and how it works
- Indication: Approved for adults with symptomatic obstructive HCM to improve functional capacity and reduce LVOT obstruction.
- How it works: It’s a selective cardiac myosin inhibitor. By partly reducing the heart’s contractility, it lowers the obstruction and can improve symptoms.
- How it’s used: Given daily with dose adjustments based on response and tolerability. Dosing often starts around a moderate dose and is titrated every few weeks.
- Monitoring and safety: You’ll need regular echocardiograms to measure left-ventricular ejection fraction (LVEF) and the LVOT gradient. The label recommends stopping or adjusting therapy if LVEF falls to a low level (often described as around 50% or lower, depending on your doctor’s plan) or if there are signs of reduced heart function. Common side effects include dizziness and fatigue; more serious concerns are related to reduced heart function. Your doctor will give specific guidelines for monitoring.
- Pros and cons: Pros include potential improvements in symptoms and exercise tolerance; con side effects include the risk of reducing heart function and the need for ongoing testing.
What aficamten is (and who makes it)
- Company: Cytokinetics is developing aficamten.
- Status: Investigational and not approved yet. It’s studied as another way to treat hypertrophic cardiomyopathy by the same basic mechanism (cardiac myosin inhibition) but with its own pharmacology and trial data.
- What the data suggest (in general terms): Early studies have shown dose‑dependent effects on the heart’s function and on the obstruction, with safety signals focused on heart function (like potential reductions in LVEF). Long-term safety and real-world effectiveness are still being studied in ongoing trials.
- Availability: Not available as an approved medicine. You would access it only through a clinical trial if you’re eligible and a trial is open in your area.
Potential differences between Camzyos and aficamten
- Approval status: Camzyos is approved and available; aficamten is experimental.
- Dosing/monitoring: Camzyos has established dosing and monitoring guidelines in its labeling; aficamten dosing and safety monitoring are defined by its clinical trials but not by an approved label yet.
- Pharmacology: Both target cardiac myosin, but they are different molecules with separate pharmacokinetics and safety profiles. Some clinicians hope aficamten might offer more flexible management (for example, a shorter half-life could allow quicker reversibility), but that remains to be proven in approved use.
- Real-world data: Camzyos has FDA-approved data and follow-up experience from treated patients; aficamten hasn’t reached the same level of real-world use since it isn’t approved yet.
If your doctor is considering aficamten as an option
- Ask about the rationale: Why might aficamten be chosen over or in addition to Camzyos? Is there evidence suggesting it could be more effective or easier to manage in your case?
- Inquire about access: If your doctor is thinking about a trial, ask about eligibility, where trials are located, and what would be required (tests, visits, possible reimbursement issues).
- Clarify monitoring and safety: How would monitoring differ from Camzyos? What happens if LVEF declines or if you have side effects?
- Clarify timelines: When might aficamten be available as an approved treatment, if ever? Trials can take years, and not all candidates finish development.
What I can help with
- If you want, I can:
- Provide a side-by-side plain-language comparison of Camzyos and aficamten.
- Help you prepare questions for your doctor so you have a clear discussion about your specific case.
- Summarize the latest publicly available trial results for aficamten (without medical advice) if you tell me the latest data you’ve seen or a date range.
- Look up official labeling or trial status updates for your country, if you tell me where you are.
A quick safety reminder
- I’m not a doctor. Decisions about changing therapies should be made with your healthcare provider, who can consider your medical history, current meds, and test results.
- If you’re already on Camzyos, don’t stop or change the dose without your doctor’s guidance, and keep up with your scheduled echocardiograms.
Would you like a concise, side-by-side summary you can print or a short list of questions to ask your doctor about aficamten and Camzyos? If you’re in a specific country, I can pull in the latest regulatory status for you.